Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/35404
Title: | Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR | Authors: | Van Mieghem, Nicolas M. Unverdorben, Martin Hengstenberg, Christian Moellmann, Helge Mehran, Roxana Lopez-Otero, Diego Nombela-Franco, Luis Moreno, Raul Nordbeck, Peter Thiele, Holger Lang, Irene Zamorano, Jose L. Shawl, Fayaz Yamamoto, Masanori Watanabe, Yusuke Hayashida, Kentaro Hambrecht, Rainer Meincke, Felix VRANCKX, Pascal Boersma, Eric Rodes-Cabau, Josep Ohlmann, Patrick Capranzano, Piera Kim, Hyo-Soo Pilgrim, Thomas Anderson, Richard Baber, Usman Duggal, Anil Laeis, Petra Lanz, Hans Valgimigli, Marco Veltkamp, Roland Saito, Shigeru Dangas, George D. Jin, James Chen, Cathy |
Issue Date: | 2021 | Publisher: | MASSACHUSETTS MEDICAL SOC | Source: | The New England journal of medicine (Print), 385 (23) , p. 2150-2160 | Abstract: | Background The role of direct oral anticoagulants as compared with vitamin K antagonists for atrial fibrillation after successful transcatheter aortic-valve replacement (TAVR) has not been well studied. Methods We conducted a multicenter, prospective, randomized, open-label, adjudicator-masked trial comparing edoxaban with vitamin K antagonists in patients with prevalent or incident atrial fibrillation as the indication for oral anticoagulation after successful TAVR. The primary efficacy outcome was a composite of adverse events consisting of death from any cause, myocardial infarction, ischemic stroke, systemic thromboembolism, valve thrombosis, or major bleeding. The primary safety outcome was major bleeding. On the basis of a hierarchical testing plan, the primary efficacy and safety outcomes were tested sequentially for noninferiority, with noninferiority of edoxaban established if the upper boundary of the 95% confidence interval for the hazard ratio did not exceed 1.38. Superiority testing of edoxaban for efficacy would follow if noninferiority and superiority were established for major bleeding. Results A total of 1426 patients were enrolled (713 in each group). The mean age of the patients was 82.1 years, and 47.5% of the patients were women. Almost all the patients had atrial fibrillation before TAVR. The rate of the composite primary efficacy outcome was 17.3 per 100 person-years in the edoxaban group and 16.5 per 100 person-years in the vitamin K antagonist group (hazard ratio, 1.05; 95% confidence interval [CI], 0.85 to 1.31; P=0.01 for noninferiority). Rates of major bleeding were 9.7 per 100 person-years and 7.0 per 100 person-years, respectively (hazard ratio, 1.40; 95% CI, 1.03 to 1.91; P=0.93 for noninferiority); the difference between groups was mainly due to more gastrointestinal bleeding with edoxaban. Rates of death from any cause or stroke were 10.0 per 100 person-years in the edoxaban group and 11.7 per 100 person-years in the vitamin K antagonist group (hazard ratio, 0.85; 95% CI, 0.66 to 1.11). Conclusions In patients with mainly prevalent atrial fibrillation who underwent successful TAVR, edoxaban was noninferior to vitamin K antagonists as determined by a hazard ratio margin of 38% for a composite primary outcome of adverse clinical events. The incidence of major bleeding was higher with edoxaban than with vitamin K antagonists. (Funded by Daiichi Sankyo; ENVISAGE-TAVI AF ClinicalTrials.gov number, .) Edoxaban for Atrial Fibrillation with TAVR In a randomized trial involving patients who had atrial fibrillation after TAVR, edoxaban was noninferior to vitamin K antagonists with respect to a composite outcome of death, MI, stroke, thromboembolism, valve thrombosis, or major bleeding but was associated with a higher incidence of major bleeding. | Notes: | Dangas, GD (corresponding author), Univ Hosp Heidelberg, Dept Neurol, Heidelberg, Germany.; Dangas, GD (corresponding author), Natl & Kapodistrian Univ Athens, Sch Med, Athens, Greece. george.dangas@mountsinai.org |
Document URI: | http://hdl.handle.net/1942/35404 | ISSN: | 0028-4793 | e-ISSN: | 1533-4406 | DOI: | 10.1056/NEJMoa2111016 | ISI #: | 000691651500001 | Rights: | 2021 Massachusetts Medical Society. All rights reserved. | Category: | A1 | Type: | Journal Contribution |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR.pdf Restricted Access | Published version | 432.56 kB | Adobe PDF | View/Open Request a copy |
WEB OF SCIENCETM
Citations
148
checked on Sep 27, 2024
Page view(s)
62
checked on Jul 24, 2023
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.